Access Pfizer’s drug development expertise, publishing rights and its Centers for Therapeutic Innovation (CTI) foundation partners through research. The CTI and NIH are now accepting proposals for collaborative projects that focus on translational therapeutic drug targets.
Pfizer’s CTI pairs NIH intramural researchers with Pfizer scientists to pursue scientific and medical advances through joint research and development projects. The CTI model is the first NIH-wide biologics initiative with a pharmaceutical partner that NCATS coordinates on behalf of all NIH intramural researchers. The goal of the program is to identify biologic compounds with activity in a pathway or target of interest to an NIH intramural researcher and to Pfizer. Together, the scientific team works to move these compounds through laboratory testing and into clinical evaluation.